Furthermore, genetically modified MSCs that overexpress IL-37 demonstrate superior immunosuppressive properties compared to standard MSCs or IL-37, suggesting that genetically modified MSCs are more effective in managing SLE. The gene discussed is IL37; the disease is systemic lupus erythematosus.